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Background: Traditional standard triple therapy for Helicobacter pylori (H. pylori) infection 
(proton pump inhibitor-clarithromycin-amoxicillin) can easily be converted to non-bismuth 
quadruple (concomitant) therapy by the addition of a nitroimidazole twice daily.
Aim: To critically review evidence on the role of non-bismuth quadruple therapy (proton pump 
inhibitor-clarithromycin-amoxicillin-nitroimidazole) in the treatment of H. pylori infection.
Methods: Bibliographical searches were performed in MEDLINE and relevant congresses up 
to December 2011. We performed a meta-analysis of the studies evaluating the concomitant 
therapy, and of the randomized controlled trials comparing the concomitant and the standard 
triple therapy.
Results: A meta-analysis of 19 studies (2070 patients) revealed a mean H. pylori cure rate 
(intention-to-treat) of 88% (95% confidence interval from 85% to 91%) for non-bismuth qua-
druple therapy. We performed a meta-analysis of the randomized controlled studies compar-
ing the concomitant (481 patients) and the standard triple therapy (503 patients). The former 
was more effective than the latter: 90% versus 78% (intention-to-treat analysis). Results were 
homogeneous (I  2 = 0%). The odds ratio for this comparison was 2.36 (95% confidence interval 
from 1.67 to 3.34). A tendency toward better results with longer treatments (7–10 days versus 
3–5 days) has been observed, so it seems reasonable to recommend the length of treatment 
achieving the highest cure rates (10 days). Clarithromycin resistance may reduce the efficacy 
of non-bismuth quadruple therapy, although the decrease in eradication rates seems to be far 
lower than in standard triple therapy. Experience with the non-bismuth quadruple therapy in 
patients with metronidazole-resistant strains is still very limited.
Conclusion: Non-bismuth quadruple (concomitant) therapy appears to be an effective, safe, 
and well-tolerated alternative to triple therapy and is less complex than sequential therapy. 
Therefore, this regimen appears well suited for use in settings where the efficacy of triple 
therapy is unacceptably low.
Keywords: Helicobacter pylori, concomitant therapy, sequential therapy, clarithromycin, 
metronidazole, non-bismuth quadruple
Introduction
Helicobacter pylori (H. pylori) infects approximately 50% of the adult population 
and is associated with a wide range of upper gastrointestinal diseases including 
gastritis, peptic ulcer disease, and gastric cancer.1 The most widely recommended 
treatment in international guidelines for the eradication of H. pylori is the so called 
standard, or proton pump inhibitor (PPI)-based, triple therapy, which combines two 
antibiotics (clarithromycin plus amoxicillin or metronidazole) with a PPI for at least 
7 days.2–6 However, since the microorganism was discovered, the eradication rates 
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have fallen considerably with this regimen.7,8 Two recent 
double-blind, US multicenter studies both found disappoint-
ingly low eradication rates with standard therapy (77%),9,10 
and two meta-analyses including more than 53,000 patients 
revealed the cure rate to be below 80%.11,12 Therefore, the 
ethics of continued use of standard triple therapy have 
recently been questioned, and alternative approaches 
have been   recommended.13 Attempts to increase the duration 
of triple therapy, thus prolonging exposure to antibiotics, 
have achieved controversial results, but have not generally 
resulted in remarkable benefits.14,15   Consequently, new 
strategies to improve first-line treatment are still urgently 
needed.
One recent innovation, postulated as an alternative to stan-
dard triple therapy, is sequential treatment, which involves 
a simple dual regimen including a PPI plus   amoxicillin for 
the first 5 days followed by a triple regimen including a PPI, 
clarithromycin, and tinidazole for the   following 5 days.16 
  Several randomized clinical trials (including pooled-data 
analyses and meta-analyses) have demonstrated that a 
sequential regimen is more effective than standard triple 
therapy.17–21 Therefore, some guidelines have proposed 
sequential therapy as an alternative to standard triple 
therapy for the eradication of H. pylori.22 However, a recent 
update of previous meta-analyses performed by a Cochrane 
  Collaboration group23 found that the results obtained with 
the sequential regimen were clearly heterogeneous, and 
that several recently published studies were unable to dem-
onstrate differences between sequential and standard triple 
therapy. So, although the overall mean eradication rate with 
the sequential regimen was nearly 90%, a tendency towards 
lower efficacy with this regimen was observed in the more 
recent studies.24–27
Moreover, a relevant question is whether it is necessary to 
provide the drugs sequentially or if the four constituent com-
ponents of sequential therapy can be given concurrently.28,29 
In other words, does sequential administration represent 
an advantage or does it make therapy more complicated 
than necessary?13,30 In this regard, the triple combination of 
clarithromycin plus amoxicillin and a nitroimidazole with a 
PPI (but without bismuth) has previously been examined as a 
nonsequential regimen, which proved effective. The concept 
of a “non-bismuth quadruple regimen” or “concomitant” 
regimen (the term used hereafter) has recently resurfaced.31 
Traditional standard triple therapy (PPI-clarithromycin-
amoxicillin) can easily be converted to concomitant therapy 
by the addition of 500 mg of metronidazole or tinidazole 
twice daily.32
The aim of the present article is to critically review 
  evidence on the role of concomitant therapy in the treatment 
of H. pylori infection. We review the following aspects: 
rationale for use, efficacy of the regimen and the variables 
affecting it, comparison between the concomitant regimen 
and standard triple and sequential therapy, and finally, 
  limitations of the concomitant regimen.
Search strategy
Bibliographical searches were performed in MEDLINE up 
to December 2011 using the following keywords (all fields): 
(“Helicobacter pylori” OR “H. pylori”) AND   concomitant 
OR concurrent OR quadruple OR (clarithromycin AND 
[amoxicillin OR amoxycillin]) AND (metronidazole OR 
tinidazole OR nitroimidazole). Articles published in any lan-
guage were included. Reference lists from the trials selected 
in the electronic search were hand-searched to identify 
further relevant trials. We also conducted a manual search 
of abstracts from the scientific meetings of the International 
Workshop of the European Helicobacter Study Group, the 
United European Gastroenterology Week, and the American 
Digestive Disease Week. Abstracts of the articles selected 
in each of these multiple searches were reviewed, and those 
meeting the inclusion criteria were selected. References 
from reviews on H. pylori treatment with the concomitant 
regimen and from the works selected for the study were also 
examined to identify articles meeting the inclusion criteria. 
In the case of duplicate reports or studies obviously report-
ing results from the same study population, only the latest 
published data were used.
Rationale/historical perspective  
of the concomitant regimen
In 1998, two groups of investigators, one in Germany and the 
other in Japan, proposed that a PPI, amoxicillin, clarithro-
mycin, and nitroimidazole be given concurrently as a nonse-
quential four-drug, three-antibiotic, non-bismuth-containing 
quadruple regimen.33,34 Despite the short duration of therapy 
(5 days on average), this approach provided high cure rates 
(.90% by intention-to-treat).
The efficacy of a triple regimen (PPI, clarithromycin, 
and a nitroimidazole) was known to be inversely related to 
bacterial load, and higher eradication rates were achieved 
in patients with a low bacterial density in the stomach.35–37 
Therefore, the addition of amoxicillin lowered bacterial 
load in the stomach, with the consequent improvement in 
the efficacy of the short course of triple therapy.38 In other 
words, concurrent administration of the three antibiotics as 
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concomitant therapy proved more efficacious than when they 
were administered separately.39
Proponents of sequential treatment (amoxicillin for 
5 days, followed by clarithromycin plus a nitroimidazole for a 
further 5 days) argue that initial use of amoxicillin could pro-
vide a key advantage in the eradication of H. pylori.18 namely, 
prevention of the selection of secondary   clarithromycin 
resistance.40 Indeed, it is known that bacteria can develop 
efflux channels for clarithromycin, which rapidly transfer 
the drug out of the bacterial cell, preventing the binding 
of the antibiotic to the ribosome.41–43 It has been speculated 
that the disruption of the cell wall caused by amoxicillin 
prevents the development of efflux channels by damaging 
the cell wall of the bacterium. In theory, this disruption 
could help to improve the efficacy of clarithromycin in the 
second phase of treatment.40,44 However, the improved effect 
with sequential (and concomitant) therapy – as compared 
with standard triple therapy – may not be due to sequential 
administration itself, but to the larger number of antibiotics 
(three drugs) to which the organism is exposed or to the use 
of a nitroimidazole, which is not contained in the standard 
triple-drug regimen.45,46
Efficacy of the concomitant regimen 
for eradication of H. pylori
Studies evaluating the efficacy of the concomitant   regimen are 
summarized in Table 1.33,34,47–63 These studies were performed 
in different countries in Europe, Asia, and America, and 
most were randomized controlled trials. Similar concomitant 
regimens were prescribed, with only minor modifications, 
namely, the PPI (omeprazole, lansoprazole, rabeprazole, 
or esomeprazole) and the nitroimidazole   (metronidazole or 
tinidazole). However, duration of treatment varied mark-
edly between 3 and 14 days (see below). Our analysis of the 
19 studies (2070 patients) revealed a mean H. pylori cure rate 
(intention-to-treat) of 88% (95% confidence interval [95% 
CI] from 85% to 91%) (Table 2). The data were combined 
using the generic inverse variance method, which involves a 
weighted average of the effect estimates from the individual 
studies. The weight for each study is taken to be the inverse 
of the variance (one divided by the square of the standard 
error) of the effect estimate. As results were heterogeneous 
(P , 0.001; I  2 = 80%), a random effect model   (DerSimonian 
and Laird) was applied to perform the meta-analysis (using 
Review Manager 5.0.25, developed by the Cochrane 
Collaboration).
From those studies, the one performed in Latin 
America (including patients from Chile, Colombia, Costa 
Rica,   Honduras, Mexico, and Nicaragua) had markedly 
  disappointing results, with a 74% eradication rate.57 The 
explanation for this outlier is unclear, as information on 
the antibiotic susceptibility of H. pylori is not available in 
the article. Furthermore, even though the treatment lasted 
only 5 days, other studies with the same period of adminis-
tration performed some years ago obtained excellent results 
(.90%) (see below for a more detailed discussion on the 
duration of treatment). We might speculate that 5-day con-
comitant regimens were effective enough a decade ago, but 
that increased antibiotic resistance rates have revealed the 
need for longer regimens.
A second outlier study was performed by Toros et al60 
in Turkey, where only a 75% eradication rate was achieved 
despite the fact that high doses of metronidazole (500 mg 
three times daily) were used and a 14-day regimen was 
  prescribed. It should be taken into consideration that, in 
  Turkey, results with the standard triple therapy have also been 
far lower than expected. Thus, in a large randomized trial 
performed in Turkey, H. pylori eradication rates achieved 
with a PPI-clarithromycin-amoxicillin regimen for 7 and 
14 days were only 24% and 43%, respectively.64
Finally, a third outlier study was performed by Choi et al63 
in Korea, where only a 63% cure rate was reported, although 
the study has not yet been published as a peer-reviewed article 
and only 38 patients were included.
The cure rates recorded in the remaining studies 
were .80% and even .90%. In fact, if these three outlier 
studies are excluded, the mean eradication rate (intention-
to-treat) of the remaining 16 studies increased to 91%, and 
the interstudy heterogeneity almost completely disappeared 
(I  2 = 10%).
Effects of different variables on the 
efficacy of concomitant therapy
The efficacy of the concomitant regimen on H. pylori 
  eradication depends on several factors.
Clarithromycin resistance
Resistance rates for antimicrobial agents rise with indis-
criminate use, and clarithromycin resistance may be due to 
the widespread use of this agent for upper respiratory tract 
infections.65,66 Antimicrobial resistance is largely responsible 
for the poor eradication rates with standard triple therapy.67–69 
Culture and antimicrobial sensitivity testing of H. pylori 
are not widely available and, when they are, they may not 
produce any clear clinical benefit.32,70–72 One meta-analysis 
reported an almost 60% decline in eradication rates with 
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standard triple therapy if clarithromycin resistance was 
present.67,73 Therefore, the use of standard triple therapy has 
been recommended only in those areas where clarithromycin 
resistance is lower than 15%–20%.2
Clarithromycin resistance reduces the efficacy of sequen-
tial therapy, although the decrease in eradication rates was 
far lower than in triple therapy.16,18–21,45,74 Therefore, the 
sequential treatment regimen may be preferable to triple 
therapy when the prevalence of clarithromycin-resistant 
H. pylori infection is high, which is the case in many devel-
oped countries.45
This advantage of sequential therapy over standard triple 
therapy (ie, higher eradication rates among patients with 
clarithromycin resistance) also seems to be applicable to 
concomitant therapy. An initial meta-analysis determined 
the effect of drug resistance on the efficacy of first-line treat-
ment regimens for H. pylori and identified the most effective 
treatments in the presence of drug resistance; the results 
showed that resistance to clarithromycin or metronidazole 
may be overcome by using quadruple therapies, especially 
those containing both clarithromycin and   metronidazole.69 
The effect of clarithromycin resistance on the efficacy of 
concomitant regimens was negligible, with 95%   efficacy 
in the   clarithromycin-sensitive arm, and 96% in the 
  clarithromycin-resistant arm.69 Nevertheless, this conclusion 
was based on only two studies.53,54 More recently, Wu et al56 
found no significant effect of antibiotic resistance on the 
efficacy of concomitant therapy: H. pylori was eradicated in 
three out of four (75%) clarithromycin-resistant patients.
Finally, Molina-Infante et al75 recently compared qua-
druple concomitant therapy and standard triple therapy for 
clarithromycin-susceptible H. pylori strains. A statistically 
nonsignificant tendency (P = 0.2) to better results was 
observed with concomitant therapy compared with standard 
triple therapy, both by per-protocol (88% versus 78%) and 
by intention-to-treat (88% versus 73%) analysis. Therefore, 
quadruple concomitant therapy may be more effective than 
standard triple therapy even for clarithromycin-susceptible 
H. pylori.
Indirect evidence supporting an advantage of a con-
comitant regimen over a sequential regimen comes from a 
recent study.50 The authors evaluated the efficacy of empiric 
concomitant therapy in a geographical area (Spain) where 
sequential therapy had previously proved inefficient (76% cure 
rate in a prior study24). Eradication rates for the concomitant 
regimen were 88% by per-protocol analysis and 85% by 
intention-to-treat analysis, and the authors concluded that in 
settings with high clarithromycin resistance (.5%–20%) and 
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Study or 
subgroup
Calvet et al47
Catalano  et al48
Chan et al49
Choi et al63 
Greenberg et al57
Kim et al59 
Kongchayanun et al58
Kongchayanun et al58 
Kwon61 
Kwon61 
Molina-Infante et al50  
Moon et al62
  Nagahara et al51
Nagahara et al52
Neville et al53
Okada et al34
Okada et al54
Toros et al60
  Treiber et al33
  Treiber et al55
Treiber et al55
  Wu et al56
Total (95%CI) 
Heterogeneity: Tau² = 0.00; Chi² = 107.58, df = 21 (P < 0.00001); I² = 80%
Test for overall effect: Z = 53.68 (P < 0.00001) 
Eradication 
rate
0.875
0.893
0.939
0.632
0.736
0.91
0.9
0.96
0.875
0.9
0.864
0.81
0.945
0.925
0.875
0.944
0.917
0.75
0.913
0.813
0.892
0.93
SE
0.044
0.041
0.042
0.078
0.02
0.024
0.042
0.028
0.048
0.043
0.038
0.054
0.031
0.029
0.044
0.024
0.021
0.047
0.042
0.044
0.034
0.024
Weight
4.2%
4.4%
4.3%
2.6%
5.5%
5.3%
4.3%
5.1%
4.0%
4.3%
4.6%
3.6%
5.0%
5.1%
4.2%
5.3%
5.5%
4.0%
4.3%
4.2%
4.8%
5.3%
100.0%
0.88 [0.79, 0.96]
0.89 [0.81, 0.97]
0.94 [0.86, 1.02]
0.63 [0.48, 0.78]
0.74 [0.70, 0.78]
0.91 [0.86, 0.96]
0.90 [0.82, 0.98]
0.96 [0.91, 1.01]
0.88 [0.78, 0.97]
0.90 [0.82, 0.98]
0.86 [0.79, 0.94]
0.81 [0.71, 0.92]
0.94 [0.88, 1.01]
0.93 [0.87, 0.98]
0.88 [0.79, 0.96]
0.94 [0.90, 0.99]
0.92 [0.88, 0.96]
0.75 [0.66, 0.84]
0.91 [0.83, 1.00]
0.81 [0.73, 0.90]
0.89 [0.83, 0.96]
0.93 [0.88, 0.98]
0.88 [0.85, 0.91]
Eradication rate
IV, random, 95% CI
Eradication rate
IV, random, 95% CI 
−1 −0.5 0 0.5 1
Abbreviations: CI, confidence interval; IV, inverse variance; SE, standard error.
Table 2 Meta-analysis of efficacy (intention-to-treat) of studies evaluating the concomitant regimen for the treatment of Helicobacter 
pylori infection
documented failure of sequential therapy, concomitant therapy 
may achieve acceptable eradication rates.50 The reason for this 
theoretical advantage of concomitant therapy over sequential 
therapy (which should be confirmed in randomized controlled 
trials including both regimens in the same study) may be a 
lower effect of antibiotic resistance on the eradication rate 
with concomitant therapy (when all three antibiotics are 
administered concurrently) or the longer period of time each 
antibiotic is prescribed (5 days in the sequential regimen and 
7–10 days in the 7 to 10-day concomitant regimen).
Nitroimidazole resistance
Despite the inclusion of tinidazole, it has been suggested 
that the sequential regimen may achieve a significantly 
higher eradication rate than the tinidazole-free standard 
triple therapies.20 On the other hand, experience with 
concomitant therapy in patients with metronidazole-
resistant strains is still very limited. In the study by 
Neville et al,53 similar eradication rates against both 
  metronidazole-sensitive (95%) and metronidazole-resistant 
(85%) strains were achieved with the concomitant regimen. 
Okada et al54 found that H. pylori was eradicated in 25 out 
of 27 (93%) patients with   metronidazole-resistant strains 
compared with 130 out of 136 (96%) patients with metron-
idazole-sensitive strains. However, Treiber et al55 observed 
that 5-day concomitant treatment eradicated H. pylori in 90% 
of   metronidazole-susceptible patients but in only 50% (8/16) 
of metronidazole-resistant patients. Finally, bismuth-based 
quadruple therapy has been proposed as a means of over-
coming imidazole resistance, and it remains to be seen how 
concomitant therapy would perform in comparison.76
Dual clarithromycin and metronidazole 
resistance
Sequential therapy has been reported to be absolutely 
  ineffective in patients with dual resistance (clarithromycin 
and imidazole).45 Primary dual resistance for clarithromycin 
and imidazole has been shown to produce an eradication rate 
of 50% (2/4) following 5 days of concomitant therapy55 and 
75% (3/4) after 7 days of concomitant therapy.54
Comparative studies where both sequential and con-
comitant regimens are administered are clearly necessary. 
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In this respect, Wu et al56 compared the efficacy of   sequential 
and concomitant therapy and analyzed the effects of   antibiotic 
resistance. Dual resistance did not influence the level of eradi-
cation in the concomitant therapy group, but significantly 
affected that of the sequential therapy group. In particular, 
patients with dual resistance had a significantly lower eradi-
cation rate after sequential therapy (present   versus absent: 
33.3% versus 95.1%; P , 0.0001), but not after concomi-
tant therapy (75.0% versus 92.4%, respectively; P = 0.22; 
although the low number of patients makes the possibility 
of a type II error likely).
Finally, Molina-Infante et al75 recently compared quadru-
ple concomitant and sequential therapies for clarithromycin-
resistant and dual clarithromycin and metronidazole resistant 
strains. Per-protocol and intention-to-treat eradication rates 
for clarithromycin-resistant strains with concomitant and 
sequential treatments were 100% (4/4) and 80% (4/5), and 
for dual clarithromycin- and metronidazole-resistant strains 
they were 66% (2/3) and 75% (3/4). Therefore, the authors 
concluded that both quadruple concomitant and sequential 
regimens may maintain acceptable eradication rates for 
clarithromycin-resistant and for dual clarithromycin- and 
metronidazole-resistant strains.
In summary, concomitant therapy may be more suitable 
than sequential therapy for patients with dual resistance to 
antibiotics. Nevertheless, one would suspect that neither 
concomitant nor sequential therapy would be a good choice 
in the face of known dual resistance.13 In any case, these 
considerations are based on results from small samples; 
therefore, more data are needed before a reliable conclusion 
can be drawn.
Duration of treatment
Non-bismuth quadruple (concomitant) therapy was originally 
developed in an attempt to decrease the duration of treatment 
for H. pylori infection. In studies performed in the late 1990s, 
data from Europe and Japan suggested that a short course 
of 3–5 days with three antibiotics and a PPI could achieve 
reasonable eradication rates.66
In their meta-analysis (nine studies), Essa et al77 showed 
that, despite the very short treatment durations of some of 
the trials, concomitant therapy yielded excellent results but 
duration of therapy became a significant variable, with longer 
duration tending to produce higher eradication rates.
The results of the studies included in Tables 1 and 2 
show that, depending on the duration of treatment, mean 
H. pylori eradication rates for concomitant treatment were: 
3 days (85%), 4 days (88%), 5 days (83%), 7 days (91%), 
and 10 days (90%). Therefore, a trend toward better results 
with longer treatments was observed.
The only randomized trial to date that has compared 
a 5-day regimen of concomitant therapy with a 10-day 
  regimen58 revealed a nonsignificant trend for higher cure rates 
with the longer regimen (96% with 10 days versus 90% with 
5 days). Although the authors conclude that both durations 
were “similar”, a type II error may not be ruled out, and this 
6% difference may be clinically relevant.
The real benefit of a highly effective first-line therapy 
is much greater than the raw percentage data suggest.78 As 
safety is similar and the increase in costs relatively low, it 
seems reasonable to recommend the length of treatment 
achieving maximal cure rates (10 days), even though the 
expected improvements will be moderate.
Comparison between the 
concomitant regimen and  
the standard triple regimen
Efficacy
Several randomized studies have confirmed the   superiority 
of concomitant therapy over standard triple therapy. A recent 
meta-analysis77 examined nine prospective trials treating 
H. pylori for up to 7 days with a concomitant regimen (PPI-
macrolide-imidazole-amoxicillin). Treatment generally 
lasted 5 days (4 days in one study and 7 days in another). 
Overall, concomitant therapy was effective in 90% of patients 
in the intention-to-treat analysis and 93% in the per-protocol 
analysis. Pooled estimates of the five randomized controlled 
trials showed the superiority of concomitant therapy over 
triple therapy (odds ratio of 2.86; 95% CI, 1.73–4.73).
We recently updated these analyses with a more recent 
study59 and have performed a meta-analysis including the 
randomized controlled studies that, to date (December 2011), 
have compared these two regimens. As summarized in 
Table 3, 481 patients received the concomitant regimen and 
503 the standard triple regimen. The former was more effec-
tive than the latter: 90% versus 78% in the intention-to-treat 
analysis. As the results were very homogeneous (I  2 = 0%), 
a fixed effect model (Peto method) was used to perform the 
meta-analysis (Review Manager 5.0.25). The odds ratio for 
this comparison was 2.36 (95% CI, 1.67–3.34) (Table 3).
Tolerance
In the meta-analysis by Essa et al,77 no severe side effects 
were reported in any of the studies, apart from anaphylactic 
reactions to medication.34,54,55 Mild to moderate side effects 
were reported in 27%–51% of patients treated with the 
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Study or 
subgroup
Treiber et al33
Neville et al53
Nagahara et al51
Catalano et al48
Nagahara et al52
Moon et al62
Kim et al59
Total (95% CI)
Total events
Heterogeneity: Chi2 = 4.76, df = 6 (P = 0.57); I2 = 0%
Test for overall effect: Z = 4.85 (P < 0.00001)
42
49
52
50
74
43
123
433
Total
46
56
55
56
80
53
135
481
38
33
40
45
65
55
116
392
Total
42
56
50
55
80
85
135
503
Weight
5.7%
17.3%
9.0%
10.8%
14.4%
21.2%
21.6%
100.0%
1.10 [0.26, 4.69]
4.24 [1.84, 9.74]
3.77 [1.19, 12.00]
1.82 [0.63, 5.23]
2.67 [1.07, 6.65]
2.21 [1.04, 4.69]
1.66 [0.79, 3.51]
2.36 [1.67, 3.34]
Year
1998
1999
2000
2000
2001
2011
2011
Concomitant
events
Standard
events
Peto odds ratio
peto, fixed, 95% CI
Peto odds ratio
peto, fixed, 95% CI
0.005 0.1 1 10 200
Concomitant therapy Standard therapy
Abbreviation: CI, confidence interval.
Table 3 Meta-analysis comparing the efficacy (intention-to-treat) of the concomitant regimen with that of standard triple therapy for 
the eradication of Helicobacter pylori infection
concomitant regimen (compared with 21%–48% of patients 
treated with triple therapy).77 These observations suggest 
that concomitant and standard triple therapies have a similar 
safety profile.
Comparison between concomitant 
and sequential regimens
One potential problem with sequential therapy is its complex-
ity, as it requires switching from a dual to a triple therapy 
half way through treatment. Therefore, trials comparing 
  sequential with concomitant therapy using the same combina-
tion of drugs are necessary. Such comparisons would address 
whether the sequential element of sequential quadruple 
therapy is actually helpful.30 A direct head-to-head compari-
son between sequential and concomitant therapy would also 
tell us which of these two competitors can eventually replace 
the current first-line triple therapies.79
In this respect, Wu et al56 recently performed a multicenter 
randomized comparison of 10-day sequential therapy with 
10-day concomitant therapy, including 232 H. pylori-infected 
patients from three hospitals in Taiwan. Intention-to-treat 
eradication rates were similar for both regimens: 92% versus 
93%, respectively. Per-protocol cure rates were exactly the 
same: 93% with both regimens. The frequency of adverse 
events was also similar (31% versus 27%), as was adher-
ence to therapy (96% versus 98%). Therefore, the authors 
concluded that sequential and concomitant administration of 
the same drugs provides similar results in terms of efficacy 
and safety and that the sequential administration protocol 
may produce unnecessary complexity for both patients and 
physicians compared with concurrent prescription of all 
the medications from the outset.56 The study, however, was 
performed in a population with a very low rate of clarithro-
mycin and dual clarithromycin-metronidazole resistance; 
therefore, the potential advantage of concomitant therapy in 
multiresistant strains may not been adequately appreciated. 
In fact, the rate of antibiotic resistance in Taiwan is very 
low, and excellent cure rates (almost 90%) have also been 
recently reported with standard triple therapy.80
A second randomized study has compared the concomi-
tant regimen (5 days) and the sequential regimen (10 days) 
in seven Latin American populations57 and has reported 
disappointing results with both regimens (74% and 76% 
cure rates, respectively). By contrast, the eradication rate 
achieved with the standard triple therapy administered for 
14 days was statistically higher (82%).
Limitations of concomitant therapy
The results of the aforementioned studies are encouraging, 
although a number of limitations may affect the strength of 
their conclusions (see below).
Old data
Many of the previously mentioned data (see Table 1) are 
from a decade ago, when the rates of clarithromycin and met-
ronidazole resistance were quite low.66 Considering changes 
in resistance rates, these data may not be valid today.72 
As few recent data are available from Western populations 
with current rates of resistance, well-controlled   studies are 
  necessary.66 Nonetheless, a recently study published in 
complete journal format reported excellent results: 93% 
eradication both by intention-to-treat and by per-protocol 
analysis with 10-day concomitant treatment,56 suggesting 
that, at least with the 10-day regimen, favorable results 
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may still be obtained. Obviously, further robust assessment 
across a much broader range of patients is required before 
concomitant therapy can be generally recommended in clini-
cal practice.16
Small sample size and low  
quality of studies
The sample in most studies evaluating the concomitant 
regimen comprises fewer than 100 patients (Table 1). In 
particular, all the individual studies included in the only 
meta-analysis published to date had a small sample size.77 
Furthermore, the quality of the studies is low in most cases. 
Thus, there are no double-blind randomized controlled trials 
with this regimen, and only two of the trials included in the 
meta-analysis by Essa et al were single-blinded, thus limiting 
the quality of the available evidence.77
Insufficient information on the effects  
of antibiotic resistance
As most of the published studies failed to evaluate clarithro-
mycin and nitroimidazole resistance, available information 
is insufficient to truly judge this antimicrobial regimen 
according to its applicability in populations with high or low 
antimicrobial resistance.
Limitation of future treatment options 
after failure of eradication
All regimens require an adequate back-up or rescue 
therapy.70,71,79 However, it remains unclear how failure of 
concomitant therapy should be managed. One potential dis-
advantage of concomitant therapy is that patients with failed 
eradication would have limited options for further treatment, 
because they would already have received three different 
antibiotics: amoxicillin, clarithromycin, and nitroimidazole.17 
In this respect, it has been suggested that the first choice 
for eradication treatment should probably not be a regimen 
combining clarithromycin and metronidazole.70,79 Although 
this regimen is very effective, patients who are not cured 
will have at least single, and usually double, resistance,81 
and few logical empirical treatment options are subsequently 
available.79 Some authors have demonstrated that initial regi-
mens containing both clarithromycin and nitroimidazole are 
associated with significantly worse results overall, with lower 
eradication rates after logically chosen second-line therapy 
and sensitivity-directed third-line therapy; the poor results 
were due to the emergence of multiple resistant strains, as evi-
denced by culture testing after the second failed course.82
However, the recent appearance of levofloxacin may 
overcome this problem, as levofloxacin-containing rescue 
therapy constitutes an encouraging empirical second-line 
or even third-line strategy after multiple previous H. pylori 
eradication failures with key antibiotics such as   amoxicillin, 
clarithromycin, metronidazole, and tetracycline.83–85 Zullo 
et al86 recently performed a pilot study on patients who failed 
sequential therapy (a regimen including the same antibiotics 
as concomitant therapy). Following 10-day triple therapy 
with a PPI, levofloxacin, and amoxicillin, H. pylori infection 
was successfully cured in 86% of cases. In another study, 
Perna et al87 prescribed a 10-day triple regimen with a PPI, 
levofloxacin, and amoxicillin in patients in whom first treat-
ment with either standard 10-day triple or sequential therapy 
(only 10 patients) had failed. H. pylori was eradicated 
in 73% of cases, although the authors do not provide 
separate efficacy rates depending on the first (failure) 
treatment. Finally,   Gisbert et al88 evaluated the efficacy of 
a second-line levofloxacin-containing triple regimen (PPI-
amoxicillin-levofloxacin) in 35 patients after “sequential” 
or “  concomitant” treatment failure; H. pylori eradication 
rate was 80%. Respective cure rates for “sequential” and 
“  concomitant” failure regimens were 67% and 90%.
These data seem to indicate that a triple regimen (PPI-
levofloxacin-amoxicillin) is a suitable approach for second-
line treatment in patients whose sequential – and probably 
also concomitant – therapy fails.18,89,90 Therefore, the con-
comitant regimen plus levofloxacin-containing triple therapy 
may be an adequate therapeutic strategy for the management 
of H. pylori in clinical practice. However, given the rise in 
resistance to this antibiotic, the prevalence in each country 
must be taken into account.
Finally, bismuth-based quadruple therapy (ie, PPI, 
  bismuth, tetracycline, and nitroimidazole) could be an alter-
native in patients whose concomitant therapy fails. Thus, the 
results of a recent study showed that all patients who had 
failed sequential therapy (ie, a regimen including the same 
antibiotics as the concomitant therapy) were able to eradicate 
the bacterium with bismuth-based quadruple therapy.91
Conclusion
Standard triple therapy is still the most widely used treatment 
in clinical practice. However, the prevalence of clarithromy-
cin and metronidazole resistance has increased substantially 
in recent years, and there has been a corresponding decrease 
in the eradication rate for H. pylori infection. Eradication 
rates are at their lowest levels since a decade ago and are 
likely to fall further as antimicrobial resistance becomes more 
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prevalent worldwide.66 It is clear that alternative treatment 
regimens are urgently needed, particularly for patients with 
clarithromycin-resistant strains of H. pylori.92
Sequential therapy has been proposed as an alternative to 
standard triple therapy for eradication of H. pylori. However, 
the sequential approach, which may be more complicated 
than necessary, does not appear to offer specific advantages. 
In fact, the first randomized comparison of the sequential and 
the non-bismuth quadruple concomitant regimens recently 
concluded that sequential and concomitant administration of 
the same drugs provide similar results in terms of efficacy 
and safety.
Several randomized controlled trials (and one meta-
  analysis) have demonstrated that concomitant therapy is more 
effective than, and equally well tolerated as, standard triple 
therapy. Our meta-analysis of 19 studies revealed a mean 
H. pylori cure rate of roughly 90% for concomitant therapy. 
A tendency toward better results with longer treatments 
(7–10 days versus 3–5 days) with the concomitant regimen has 
been observed, so it seems reasonable to   recommend the length 
of treatment achieving the highest cure rates (10 days).
Clarithromycin resistance may reduce the efficacy of 
concomitant therapy, although the decrease in eradication 
rates seems to be far lower than in standard triple therapy. 
Therefore, it has been suggested that the concomitant regimen 
may be preferable when the prevalence of clarithromycin-
resistant H. pylori infection is high, which is the case in 
many developed countries. Experience with the concomitant 
therapy in patients with metronidazole-resistant strains is 
still very limited.
Although the aforementioned results are encouraging, 
a number of limitations should be taken into account: (1) much 
of the data previously mentioned are relatively old; (2) the 
number of patients included in most studies evaluating the 
concomitant regimen is low; (3) the concomitant regimen 
has not been sufficiently validated in clinical practice; and 
(4) there is still insufficient information on the effect of anti-
biotic resistance on efficacy.
In summary, non-bismuth quadruple concomitant therapy 
appears to be an effective, safe, and well-tolerated alternative 
to standard triple therapy and is less complex than sequential 
therapy. Therefore, this regimen appears well suited for use 
in settings where the efficacy of triple therapy is unaccept-
ably low.
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